Research in TCRs is rapidly advancing, with significant efforts focused on improving the efficacy and safety of TCR-based therapies. Innovations include the development of bispecific TCRs, which can recognize two different antigens, and the use of CRISPR technology to enhance TCR function. There is also ongoing research into the use of TCRs in combination with other immunotherapies, such as checkpoint inhibitors, to overcome immune resistance in tumors.
